T cells that recognize HER2 receptor may prevent HER2+ bc recurrence

[VDC]

Does anyone know if Dr. Czerniecki's research is adequately funded? I heard through the grape vine that his research group was moving from UPenn and I was wondering what the motivation might be for leaving UPenn. And I'm curious what the move will mean as far as trial participants! I would assume moving a laboratory would involved down time for clinical trials. I"m hoping not! But suspect there will be a period during which no additional gals will be added to his trials. Anyone know?